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ABSTRACT: Objective—A small amount of LH is necessary for 17ß-estradiol production in the ovarian folli­
cle. Human menopausal gonadotropin (hMG) contains equal amounts of PSH and LH activity, whereas 
recombinant FSH is a gonadotropin preparation without LH. The aim of the present randomized study was 
to investigate whether ovarian stimulation treatment with recombinant FSH or hMG resulted in different 
steroidal composition of follicular fluid. Methods—Antral fluid from mature follicles was collected in in 
vitro fertilization cycles and concentrations of testosterone, androstenedione, estrone, estradiol, proges­
terone, FSH, and LH were determined. Seven patients (27 samples) were treated with hMG, 6 patients (22 
samples) with recombinant FSH. Results—Androgen, estrogen, progesterone, and FSH concentrations in fol­
licular fluid tended to be lower in the group treated with recombinant FSH, but the variation was large and 
differences were statistically not significant. Conclusion—Treatment with a gonadotropin preparation con­
taining no LH resulted in adequate androgen and estrogen levels in antral fluid of the ovarian follicle in 
women with normal endocrine profiles, even during pituitary suppression by a GnRH agonist. Apparently, 
the am ount of endogenous LH was sufficient for steroid production w ith in  the fo llicle . Int 
JFertil 42(5):306-310, 1997
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INTRODUCTION
R e c o m b i n a n t  h u m a n  f s h  (recFSH)
is produced by a Chinese hamster ovary 
cell line transfected with the human FSH 
a- and (3-subunit genes [1]. It is a pure FSH 
preparation, completely devoid of LH activity, in 
contrast with purified urinary FSH preparations. 
The development of recFSH has offered an opportu­
nity to test the two-cell two-gonadotropin hypothe­
sis. This hypothesis means that LH stimulates the 
production of androgens in the theca cells of the 
ovarian follicle, while FSH stimulates aromatiza- 
tion of the androgens into estrogens in the granu­
losa cells. The estrogens produced are then secreted 
into follicular fluid and into the blood circulation.
The two-cell two-gonadotropin theory has been 
confirmed by studies in hypophysectomized imma­
ture rats [2]. RecFSH treatment augmented ovarian 
weight, while serum 17(3-estradiol concentrations 
remained low. A clinical study on a gonadotropin- 
deficient woman showed that recFSH administration 
stimulated multiple follicular growth, without a con­
comitant increase in serum estradiol levels [3], Con­
centrations of androgens and estrogens in follicular 
fluid were extremely low. Thus, LH appeared to be 
necessary for adequate ovarian stimulation with cor­
respondingly high serum estradiol concentrations.
Devroey et al [4] showed that in in vitro fertiliza­
tion (IVF) cycles, during pituitary suppression with 
GnRH agonists (GnRHa), recFSH administration 
resulted in multiple follicular growth with adequate 
serum estradiol levels. So the low amount of endoge­
nous LH, still present despite pituitary suppression by 
a GnRHa, apparently was sufficient for stimulation of 
the theca cells to produce androgens, which were aro­
matized into estradiol. Still, lower LH stimulation of 
the ovary might result in a decrease of androgen pro­
duction by the thecal cells, lower estradiol production 
by the granulosa cells, and lower follicular fluid estra­
diol concentrations. In the present randomized study 
in IVF cycles, we compared steroid levels in the antral 
fluid of mature follicles after recFSH and hMG treat­
ment. Because follicular fluid is the endocrine envi­
ronment of the oocyte, differences in the steroidal 
composition might affect oocyte quality.
METHODS 
Patients
Thirteen women undergoing IVF treatm ent for
tubal pathology or unexplained infertility partic­
ipated in the study. The inclusion criteria were: age 
between 20 and 40 years; normal endocrine serum 
profile in the early follicular phase of the cycle 
(FSH concentration below 8 IU/L, LH/FSH ratio 
less than 3, testosterone concentration below 2.5 
nmol/L, prolactin concentration below 700 mlU/L 
and thyroxin concentration between 58 and 148 
nmol/L); no hormonal medication for at least two 
menstrual cycles prior to the study; no endometrio­
sis observed on laparoscopy; both ovaries present; 
body weight between 80% and 130% of the ideal 
weight (according to the Metropolitan Height and 
Weight Tables); and no severe male subfertility of 
the partner (at least 20 x 106 sperm/mL, at least 
30% motile sperm, motility grade at least fairly 
good, at least 40% morphologically normal sperm 
and absence of anti-sperm antibodies as confirmed 
by the direct immunobead test, or a fertilization 
rate of at least 50% if the patient had had IVF 
before).
The study was approved by the hospital's Ethical 
Committee, and all the women gave their informed 
consent.
Treatment Protocol
The women were randomly divided into two 
groups: 7 women were treated w ith  hMG 
(Humegon, NV Organon, Oss, The Netherlands): 
Group A; 6 women received recFSH (Puregon, NV 
Organon): Group B. Both preparations were admin­
istered intramuscularly (i.m.) in a fixed daily dose 
of 150 IU.
In each group gonadotropin administration was 
combined with buserelin (Suprecur, Hoechst AG, 
Frankfurt, Germany) treatment which was started 
on day 1 of the menstrual cycle, in a daily dose of 
600 jizg intranasally. On the fourteenth day of 
buserelin treatment the serum estradiol concentra­
tion was measured by time-resolved fluoroim- 
munoassay (DELFIA, Wallac Oy, Turku, Finland). If 
estradiol was below 200 pmol/L, gonadotropin 
administration was started the next day. If the 
estradiol concentration was still higher than 200 
pmol/L, administration of gonadotropins was post­
poned until the estradiol level was below 200 
pmol/L. Buserelin administration was continued 
until the day of human chorionic gonadotropin 
(hCG) administration.
Int J Fértil 42
308 ■ I. Duijkers
Transvaginal ultrasonography was performed 
every other day during the stimulation phase of the 
IVF cycle to measure follicular growth and 
endometrial thickness. The administration of 
gonadotropins was discontinued as soon as at least 
three follicles had a (largest) diameter >15 mm, the 
mean diameter of the largest follicle was >20 mm, 
and the endometrial thickness was >9 mm. On the 
day these criteria were fulfilled, 10,000 IU of hCG 
were administered i.m. between 11 p.m. and 12 
midnight,
Transvaginal ultrasound-guided oocyte retrieval 
was performed 35 hours after the hCG injection. 
Follicular fluid from the four largest follicles was 
collected separately. In three patients, the fluid 
from only three follicles could be collected. The 
follicular fluid was not diluted w ith flushing 
medium or fluid from another follicle. The fluid 
was centrifuged and stored at -20°C until assayed. 
Embryo transfer was performed on the third day 
after oocyte retrieval. The luteal phase of the cycle 
was supported with progesterone, administered 
intravaginally.
Assays
Concentrations of estradiol and progesterone in fol­
licular fluid were determined by RIA, as described 
by Thomas et al [5]. Concentrations of estrone [6], 
testosterone [7], and androstenedione [8] were 
determined by RIAs developed in this laboratory. 
Concentrations of FSH and LH were measured by 
IRMA procedures [9].
Statistics
Results are expressed as median values with tenth 
and ninetieth percentiles (P10, P90)* Statistical anal­
ysis was performed using the two-sample Wilcoxon 
test (rank sum test). Correlations were detected by 
Spearman's rank correlation test. Differences with 
P < .01 were considered significant.
RESULTS
Characteristics of the IVF cycles are listed in Table
I. Median serum LH concentrations on the day of 
hCG administration were equal in the two groups, 
so administration of exogenous LH in the case of
TABLE I
Cycle characteristics of the study groups.
Group A Group B
Treatment Humegon Puregon
No. patients 7 6
No, treatment days 11 (10, 11) 10(9,11|
No. follicles >15 mm 9(5, 15) 12(10, 17)
Serum estradiol 6,100 7,550
|pmol/L) * (3,660, 15,400) (5,400, 11,450)
Serum LH (IU/L) 1.4 (1.3, 1.8) 1.4 (0.9, 2.8)
No. oocytes 7 (2, 18) 11 (9, 18)
Fertilization rate (%) 86 (43, 100) 73 (62, 89)
Median values, tenth, and ninetieth percentiles in paren­
theses.
*On the day of hCG administration.
Group A did not result in an increase in serum LH 
levels of this group as compared to the Puregon 
group. The total number of follicular fluid samples 
was 27 in Group A and 22 in Group B. Median val­
ues of the hormone concentrations in the three or 
four collected follicular fluid samples were calcu­
lated for each patient. The median value of these 
individual median concentrations was determined
Median values of individual median concen­
trations of hormones in follicular fluid after 
ovarian stimulation treatment with Humegon 
(7 women) or Puregon (6 women).
Humegon Puregon
No. of samples 27 22
Testosterone (nmol/L) 14.5 (9.4, 23.5) 11.0(6.1,20.0)
Androstenedione
(nmol/L) 33 (16, 80) 19 (14, 77)
Estradiol (pmol/L) 2.4 (1.3, 3.1) 1.4 (0.7, 3.2)
Estrone (nmol/L) 145 (66, 240) 125 (54, 245)
Progesterone (pmol/L) 40(18,57) 31 (20, 39)
LH (IU/L) <1.0 <1.0
(<1.0, <1.0) (<1.0, <1.0)
FSH (IU/L) 2.2 (1.9, 3.5) 1.7 (1.2, 4.5)
Tenth and ninetieth percentiles are given in parentheses.
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in each group. The results are listed in Table II.
In both groups, high levels of androgens and estro­
gens were present in follicular fluid. Testosterone, 
androstenedione, estradiol, estrone, progesterone, 
and FSH levels tended to be lower in Group B than 
in Group A, but inter- and intra-individual varia­
tions were rather large, and the observed differences 
were not statistically significant. LH concentrations 
in follicular fluid were undetectably low in both 
groups, so administration of exogenous LH did not 
result in measurable LH immunoreactivity in antral 
fluid. No significant correlations were detected 
between the individual fertilization rates and 
median concentrations of testosterone, androstene­
dione, androgens (testosterone plus androstene­
dione], estradiol, estrone, estrogens (estradiol plus 
estrone), progesterone, the androgen/estrogen ratio, 
or the progesterone/estradiol ratio in follicular fluid.
DISCUSSION
Administration of exogenous LH did not result in 
an increase of serum LH levels in the group treated 
with hMG, probably because of the short half-life 
of LH contained in this preparation [10]. However, 
binding to the LH receptors in the theca interna 
might occur before elimination from the circula­
tion has occurred. Differences in LH binding in the 
ovary might influence the steroidal composition of 
follicular fluid, and subsequently affect oocyte 
quality.
Theoretically, one would expect that more LH 
stimulation of the ovary would lead to an increase 
of the estradiol concentration in follicular fluid for 
several reasons. First, LH stimulates androstene­
dione p roduction  in the theca in te rn a  [11]. 
Androstenedione is converted to testosterone or to 
estrone and then to estradiol in the granulosa cells 
by 17(3-hydroxy-steroid dehydrogenase and aro- 
matase. Next, estradiol is secreted into the follicu­
lar fluid [12]. Thus, an increase in androstenedione 
concentrations would lead to higher follicular fluid 
estradiol levels. Secondly, LH stimulates aromatase 
activity of granulosa cells from mature follicles 
[13]. Higher testosterone and estradiol concentra­
tions also effect FSH enhancement of aromatase 
activity [14,15], which would further increase 
estradiol production by the granulosa cells and 
thus estradiol levels in follicular fluid. Estradiol in 
turn enhances the LH stimulation of androgen pro­
duction [16]. All described effects of LH point in 
the same direction: more LH stimulation of the 
ovary invariably leads to higher estradiol concen­
trations in follicular fluid. LH also increases pro­
gesterone production in mature granulosa cells 
[13], which will result in higher progesterone con­
centrations in follicular fluid. The progesterone 
produced will serve as a potential precursor for 
androgen synthesis by the theca cells, and the 
androgens in turn are further aromatized to estro­
gens by the granulosa cells [17].
In the group treated with recFSH (Group B), 
androstenedione, estrone, estradiol, and proges­
terone concentrations in follicular fluid tended to 
be lower than in the group treated with hMG 
(Group A). This supports the theory of shortness of 
LH activity leading to a decrease of androgen, 
estrogen and progesterone production. However, 
there appears to be a large inter- and intra-individ­
ual variation, and the differences are statistically 
not significant. FSH concentrations in follicular 
fluid were slightly lower in Group B than in Group 
A. FSH stimulates aromatase activity, so lower 
FSH levels will result in a decrease in estradiol pro­
duction [18]. Furthermore, FSH induces granulosa 
cell receptors for LH [19,20], making granulosa 
cells more responsive to LH stimulation of aro­
matase activity The lower FSH levels in follicular 
fluid in Group B might, therefore, also be partly 
responsible for the slightly lower follicular fluid 
estrogen concentrations in Group B,
In conclusion, of women with normal endocrine 
profiles, treatment with recFSH resulted in ade­
quate androgen and estrogen levels in antral fluid 
of the ovarian follicle, even during pituitary sup­
pression by a GnRH-agonist. In gonadotropin-defi- 
cient women, androgen and estrogen levels in 
follicular fluid remained very low during recFSH 
treatment, due to the absence of LH [3]. In our 
study group, however, endogenous LH levels 
appeared to be sufficient to stimulate androgen pro­
duction by the theca cells. Androgen and estrogen 
concentrations in follicular fluid were only slightly 
lower after recFSH treatment than after hMG treat­
ment, so the endocrine environment of the oocyte 
will be quite similar. The observed minor differ­
ences were not statistically significant. It is pro­
posed to conduct a larger study to provide evidence 
whether androgen and estrogen concentrations 
were indeed lower when no exogenous LH was 
administered.
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